{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Growth+Hormone+Releasing+Hormone&page=3",
    "query": {
      "intervention": "Growth Hormone Releasing Hormone",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 54,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Growth+Hormone+Releasing+Hormone&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Growth+Hormone+Releasing+Hormone&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T02:08:38.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02781727",
      "title": "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Deficiency, Pediatric",
        "hGH (Human Growth Hormone)",
        "Endocrine System Diseases",
        "Hormones",
        "Pituitary Diseases"
      ],
      "interventions": [
        {
          "name": "Once weekly subcutaneous injection of TransCon hGH",
          "type": "DRUG"
        },
        {
          "name": "Once daily subcutaneous injection of Genotropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascendis Pharma Endocrinology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 162,
      "start_date": "2016-12-13",
      "completion_date": "2019-01-17",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781727"
    },
    {
      "nct_id": "NCT02748369",
      "title": "In Vivo Assessment of Cellular Metabolism in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Cellular Metabolism"
      ],
      "interventions": [
        {
          "name": "Somatostatin",
          "type": "DRUG"
        },
        {
          "name": "Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K. Sreekumaran Nair",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-07",
      "completion_date": "2017-03-02",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748369"
    },
    {
      "nct_id": "NCT03375788",
      "title": "Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease",
        "Obesity",
        "Obesity, Abdominal",
        "Liver Fat",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Tesamorelin",
          "type": "DRUG"
        },
        {
          "name": "Identical Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2019-01-17",
      "completion_date": "2025-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375788"
    },
    {
      "nct_id": "NCT02026973",
      "title": "Impact of Endogenous E2 on SSI and GH Rebound",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Somatostatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "55 Years to 80 Years · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-03-16",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02026973"
    },
    {
      "nct_id": "NCT03305016",
      "title": "A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Deficiency, Pediatric",
        "Endocrine System Diseases",
        "Hormone Deficiency",
        "Pituitary Diseases"
      ],
      "interventions": [
        {
          "name": "TransCon hGH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascendis Pharma Endocrinology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 146,
      "start_date": "2017-11-13",
      "completion_date": "2019-03-19",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03305016"
    },
    {
      "nct_id": "NCT06554717",
      "title": "Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection",
        "Frailty",
        "Impaired Physical Function",
        "Abdominal Obesity",
        "Aging"
      ],
      "interventions": [
        {
          "name": "Tesamorelin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-07-10",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06554717"
    },
    {
      "nct_id": "NCT05607004",
      "title": "(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Invasive Breast Cancer",
        "Estrogen-receptor-positive Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "(Z)-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "goserelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atossa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 87,
      "start_date": "2023-02-14",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05607004"
    },
    {
      "nct_id": "NCT01746849",
      "title": "Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lupron",
          "type": "BIOLOGICAL"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 82,
      "start_date": "2012-12",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746849"
    },
    {
      "nct_id": "NCT01632592",
      "title": "Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Abdominal Obesity"
      ],
      "interventions": [
        {
          "name": "Tesamorelin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-01",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01632592"
    },
    {
      "nct_id": "NCT00720902",
      "title": "Adult Growth Hormone Deficiency and Cardiovascular Risk",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Blood draws",
          "type": "PROCEDURE"
        },
        {
          "name": "growth hormone releasing hormone (GHRH) & arginine",
          "type": "DRUG"
        },
        {
          "name": "Carotid ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Endothelial cell biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2007-02",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-10-07T02:08:38.768Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720902"
    }
  ]
}